Javascript must be enabled to continue!
Stimuli‐Responsive Nanoparticles Combining Photodynamic Therapy and Mitochondria Disruption Suppressed Tumor Metastasis
View through CrossRef
AbstractPhotodynamic therapy (PDT) is a kind of commonly used strategy for the treatment of cancer, but tumor hypoxia severely limits the efficiency of this oxygen (O2)‐dependent modality. Disrupting mitochondria may be a promising direction to reverse the tumor hypoxia. However, to date, very few studies utilize mitochondria inhibiting strategy to complement PDT, because low permeability of mitochondria impedes the entry of therapeutic agents. A stimuli‐responsive nanoparticle system that combines PDT and mitochondria disruption strategy is reported here. The nanoparticle consists of a gelatin core that accommodates photosensitizer chlorin e6 (Ce6) and a polymeric shell that chemically attaches with mitochondria‐targeted anticancer drugs (doxorubicin‐glycyrrhetinic acid conjugates, Dox‐GA). Specifically, Ce6 produces excessive reactive oxygen species to support Dox‐GA in escaping from lysosome. Then, thanks to mitochondria targeting, Dox‐GA contributes significantly to mitochondrial dysfunction and O2 consumption depression in tumor cells, resulting in enhanced PDT. As a result, the integration of mitochondria‐targeting drug delivery and PDT shows synergistic effects in apoptosis induction, tumor growth inhibition and anti‐metastasis. The tumor metastasis is almost completely inhibited without any lung nodules observed in vivo, making it a promising strategy by integrating mitochondria‐targeting drug and PDT for metastatic breast cancer treatment.
Title: Stimuli‐Responsive Nanoparticles Combining Photodynamic Therapy and Mitochondria Disruption Suppressed Tumor Metastasis
Description:
AbstractPhotodynamic therapy (PDT) is a kind of commonly used strategy for the treatment of cancer, but tumor hypoxia severely limits the efficiency of this oxygen (O2)‐dependent modality.
Disrupting mitochondria may be a promising direction to reverse the tumor hypoxia.
However, to date, very few studies utilize mitochondria inhibiting strategy to complement PDT, because low permeability of mitochondria impedes the entry of therapeutic agents.
A stimuli‐responsive nanoparticle system that combines PDT and mitochondria disruption strategy is reported here.
The nanoparticle consists of a gelatin core that accommodates photosensitizer chlorin e6 (Ce6) and a polymeric shell that chemically attaches with mitochondria‐targeted anticancer drugs (doxorubicin‐glycyrrhetinic acid conjugates, Dox‐GA).
Specifically, Ce6 produces excessive reactive oxygen species to support Dox‐GA in escaping from lysosome.
Then, thanks to mitochondria targeting, Dox‐GA contributes significantly to mitochondrial dysfunction and O2 consumption depression in tumor cells, resulting in enhanced PDT.
As a result, the integration of mitochondria‐targeting drug delivery and PDT shows synergistic effects in apoptosis induction, tumor growth inhibition and anti‐metastasis.
The tumor metastasis is almost completely inhibited without any lung nodules observed in vivo, making it a promising strategy by integrating mitochondria‐targeting drug and PDT for metastatic breast cancer treatment.
Related Results
The effect of miRNAs and MALAT1 related with the prognosis of Her-2 positive breast cancer patients with lymph node metastasis
The effect of miRNAs and MALAT1 related with the prognosis of Her-2 positive breast cancer patients with lymph node metastasis
Abstract
Background: To analyze and screen the miRNAs associated with lymph node metastasis of breast cancer (BC), and to explore the roles of these miRNAs in the prolifera...
Antimicrobial activity of ciprofloxacin-coated gold nanoparticles on selected pathogens
Antimicrobial activity of ciprofloxacin-coated gold nanoparticles on selected pathogens
Antibiotic resistance amongst bacterial pathogens is a crisis that has been worsening over recent decades, resulting in serious and often fatal infections that cannot be treated by...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Renal Ewing Sarcoma: A Case Report and Literature Review
Renal Ewing Sarcoma: A Case Report and Literature Review
Abstract
Introduction
Primary renal Ewing sarcoma is an extremely rare and aggressive tumor, representing less than 1% of all renal tumors. This case report contributes valuable in...
Giant Sacrococcygeal Teratoma in Infant: Systematic Review
Giant Sacrococcygeal Teratoma in Infant: Systematic Review
Abstract
Introduction
Sacrococcygeal teratoma (SCT) is a rare embryonal tumor that occurs in the sacrococcygeal region, with an incidence of about 1 in 35,000 to 40,000 live births...
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract
Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...
Tumor endothelial cells accelerate tumor metastasis
Tumor endothelial cells accelerate tumor metastasis
Tumor metastasis is the main cause of cancer‐related death. Understanding the molecular mechanisms underlying tumor metastasis is crucial to control this fatal disease. Several mol...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...

